---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-007303"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T22:22:15.166015+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Revelation starts Phase 1b Gemini CKD study; shareholders approve reverse split but reincorporation fails

## Summary
- PRIME Phase 1b study of Gemini in Stage 3-4 CKD patients started; dosing mid-Feb, topline data expected mid-year.
- Shareholders approved reverse stock split (range 1:2 to 1:50) with board discretion; 3.96M for, 163K against.
- Change of domicile from Delaware to Nevada failed despite 97% of votes present in favor (2.96M for, 74K against) due to insufficient affirmative votes of outstanding shares.
- Shareholders approved issuance of shares under warrants (Dec 2024) exceeding 20% threshold; also approved meeting adjournment.
- 1,089,301 broker non-votes affected the change-of-domicile and warrant issuance proposals.

## SEC filing metadata
- accession: 0000950170-25-007303
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017025007303/0000950170-25-007303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017025007303/revb-20250117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-007303
- JSON: https://secwatch.observer/filing/0000950170-25-007303.json
- Plain text: https://secwatch.observer/filing/0000950170-25-007303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.